<?xml version="1.0" encoding="utf-8"?>
<Document>
  <Do_id>26798590</Do_id>
  <Journal>Translational lung cancer research</Journal>
  <Doc_title>Alectinib in RET-rearranged non-small cell lung cancer-Another progress in precision medicine?</Doc_title>
  <Doc_abstract>RET fusions have been recognized as potential therapeutic targets in advanced non-small cell lung cancer. RET fusion proteins are detected in about 2% of lung adenocarcinomas. Alectinib, a second generation ALK inhibitor, was shown to block growth of cells with RET fusions. Thus alectinib should be further evaluated within clinical trials in patients with RET fusion-positive adenocarcinomas of the lung. </Doc_abstract>
  <Doc_ChemicalList>None</Doc_ChemicalList>
  <Doc_meshdescriptors>None</Doc_meshdescriptors>
  <Doc_meshqualifiers>None</Doc_meshqualifiers>
</Document>
